Abstract 1937P
Background
The role of adjuvant chemotherapy for patients with a resected extremity soft tissue sarcoma (STS) is controversial. Prior individual patient data meta-analyses are limited by omission of certain randomized controlled trials. The objective of this systematic review was to reassess the efficacy of adjuvant chemotherapy in resected STS, harnessing the ability of a new method termed Kaplan Meier (KM) subtraction to obtain patient level information.
Methods
A comprehensive literature search was performed to identify RCTs of adjuvant chemotherapy for adult patients diagnosed with localized resectable soft-tissue sarcoma. We searched PubMed, Web of Science, Cochrane Controlled Trials Register, UKCCCR Register of Cancer Trials, Physicians Data Query, EMBASE, MEDLINE and CancerLit (until December 2022). Data on the following endpoints were evaluated: disease free survival (DFS) and overall survival (OS). Data were summarized as hazard ratios (HR) with 95% confidence intervals (CI). Two reviewers independently assessed eligibility and quality of the studies using a modified version of the Detsky Quality Scale. The outcome measures were disease free survival (DFS) and overall survival (OS) calculated through the fixed effect or random effect model. We applied KM subtraction in R to obtain individual patient level data from the trials for subsequent metanalysis.
Results
A total of 24 trials representing 5936 patients were be included in the final analysis. The disease-free survival hazard ratio was 1.76 (95% CI 1.38-2.24) in favour of adjuvant chemotherapy. The overall survival hazard ratio was 1.30 (95% CI 1.11-1.53) favouring adjuvant chemotherapy. For adjuvant chemotherapy with doxorubicin alone, the hazard ratio of DFS and OS were 1.78 (95% CI 1.10-2.88) and 1.47 (95% 1.01-2.13).
Conclusions
This is the largest individual patient meta-analysis to-date of adjuvant doxorubicin and ifosfamide based chemotherapy in localized resectable soft-tissue sarcoma, and confirms a survival benefit (particularly for single-agent doxorubicin) with respect to disease free survival and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15